CA2179639A1 - Compositions pour vaccins comprenant des vecteurs bacteriens vivants pour la protection contre l'infection a yersinia pestis - Google Patents

Compositions pour vaccins comprenant des vecteurs bacteriens vivants pour la protection contre l'infection a yersinia pestis

Info

Publication number
CA2179639A1
CA2179639A1 CA002179639A CA2179639A CA2179639A1 CA 2179639 A1 CA2179639 A1 CA 2179639A1 CA 002179639 A CA002179639 A CA 002179639A CA 2179639 A CA2179639 A CA 2179639A CA 2179639 A1 CA2179639 A1 CA 2179639A1
Authority
CA
Canada
Prior art keywords
plasmid
thr
organism
seq
micro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002179639A
Other languages
English (en)
Inventor
Richard William Titball
Ethel Diane Williamson
Sophie Emma Clare Leary
Angela Howells
Petra Claire Farquhar Oyston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2179639A1 publication Critical patent/CA2179639A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Nouveaux produits de recombinaison d'ADN qui sont capables de transformer des micro-organismes de telle manière que ces derniers peuvent être utilisés comme vaccins vivants ou atténués induisant une réponse immunitaire au niveau des muqueuses. Des micro-organismes ainsi transformés et des compositions pour vaccins sont également décrits. Des produits de recombinaison préférés de la présente invention sont capables de transformer des micro-organismes de telle manière que ces derniers expriment la protéine à base de F1 tout en conservant la capacité de se loger dans un environnement intestinal humain ou animal. On a identifié plusieurs produits de recombinaison capables de transformer des micro-organismes séjournant dans les intestins tels que S. typhimurium ou S. typhi pour permettre la production d'antigène F1, mais la plupart de ces produits affectent le micro-organisme de telle manière qu'il ne peut plus fonctionner efficacement dans l'intestin, tout au moins dans la mesure où il ne peut plus exprimer l'antigène, par exemple parce qu'il est instable et perd le plasmide.
CA002179639A 1993-12-24 1994-12-23 Compositions pour vaccins comprenant des vecteurs bacteriens vivants pour la protection contre l'infection a yersinia pestis Abandoned CA2179639A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9326425.7 1993-12-24
GB939326425A GB9326425D0 (en) 1993-12-24 1993-12-24 Vaccine compositions

Publications (1)

Publication Number Publication Date
CA2179639A1 true CA2179639A1 (fr) 1995-07-06

Family

ID=10747201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002179639A Abandoned CA2179639A1 (fr) 1993-12-24 1994-12-23 Compositions pour vaccins comprenant des vecteurs bacteriens vivants pour la protection contre l'infection a yersinia pestis

Country Status (6)

Country Link
EP (1) EP0741786A1 (fr)
JP (1) JPH09507028A (fr)
AU (1) AU1322295A (fr)
CA (1) CA2179639A1 (fr)
GB (1) GB9326425D0 (fr)
WO (1) WO1995018231A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070043215A1 (en) 1996-08-27 2007-02-22 Heath David G Recombinant f1-v plague vaccine
AU5597998A (en) * 1996-12-04 1998-06-29 Heska Corporation Recombinant plague vaccine
EP1176966B1 (fr) * 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire
GB9921275D0 (en) * 1999-09-10 1999-11-10 Secr Defence Recombinant microorganisms
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
GB0220257D0 (en) 2002-08-31 2002-10-09 Secr Defence Vaccine
US7344718B2 (en) 2003-01-31 2008-03-18 University Of North Dakota Yersinia species compositions
WO2012178078A2 (fr) 2011-06-22 2012-12-27 University Of North Dakota Utilisation d'une yscf, d'une yscf tronquée et d'homologues de l'yscf comme adjuvants
IN2014DN09618A (fr) 2012-05-23 2015-07-31 Us Sec Dep Of Health And Human Services

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474891A1 (fr) * 1990-09-08 1992-03-18 BEHRINGWERKE Aktiengesellschaft Vecteurs pour l'expression d'antigènes malariales sur la surface de souches vaccinales de Salmonella
DK0556333T3 (da) * 1990-11-09 2003-07-14 Univ Washington Avirulente Salmonella mikrober, der omfatter en mutation i cdt genet, og anvendelser deraf

Also Published As

Publication number Publication date
EP0741786A1 (fr) 1996-11-13
JPH09507028A (ja) 1997-07-15
GB9326425D0 (en) 1994-02-23
AU1322295A (en) 1995-07-17
WO1995018231A1 (fr) 1995-07-06

Similar Documents

Publication Publication Date Title
Vaughan et al. An aromatic-dependent mutant of the fish pathogen Aeromonas salmonicida is attenuated in fish and is effective as a live vaccine against the salmonid disease furunculosis
US6040427A (en) Vaccine
Vodkin et al. A heat shock operon in Coxiella burnetti produces a major antigen homologous to a protein in both mycobacteria and Escherichia coli
US5547664A (en) Expression of recombinant proteins in attenuated bacteria
EP0712442B1 (fr) Compositions vaccinales
Guerry et al. Development and characterization of recA mutants of Campylobacter jejuni for inclusion in attenuated vaccines
JP6329544B2 (ja) 新規生弱毒化赤痢菌属(Shigella)ワクチン
EP1368456B1 (fr) Preparations de vaccin anti-bacteriennes
EP2281834B1 (fr) Bactéries atténuées de la Famille Pasteurellaceae comprenant un gène muté de virulence
Beattie et al. Evidence that modulation requires sequences downstream of the promoters of two vir-repressed genes of Bordetella pertussis
KR101164045B1 (ko) 돼지 흉막폐렴에 대한 독성약화 생백신
EP0892054B1 (fr) Vaccine contre clostridium perfringens
CA2179639A1 (fr) Compositions pour vaccins comprenant des vecteurs bacteriens vivants pour la protection contre l'infection a yersinia pestis
Jin et al. Characterization of hgpA, a gene encoding a haemoglobin/haemoglobin-haptoglobin-binding protein of Haemophilus influenzae
US6403306B1 (en) Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
JP2798986B2 (ja) ボルデテラ・ペルタシスワクチン
AU757762B2 (en) Vaccines for chlamydia psittaci infections
EP1350796B1 (fr) Bactéries Gram négatives atténuées
EP0753061B1 (fr) Compositions vaccinales orales contre les infections a yersinia pestis
AU739191B2 (en) Vaccines containing attenuated bacteria
EP1903055A2 (fr) Protéines recombinantes d'adhésine de Haemophilus influenzae
EP0520011A1 (fr) Vaccins pour la prevention de la furonculose chez les poissons.
CA2206575A1 (fr) Bacteries vivantes attenuees de la famille ses pasteurellaceae produisant des rtx
CA2069622A1 (fr) Vaccin
WO1997008322A1 (fr) Gene mpt83 extrait de mycobacterium tuberculosis

Legal Events

Date Code Title Description
FZDE Discontinued